The opioid crisis did not begin with cartels or street corners. It began with a prescription. It began with a patient in genuine pain and a medical system that had no better answer than a pill. Fifty million Americans live with chronic pain. It is one of the most undertreated, most misunderstood, and most economically devastating conditions in medicine, and the standard of care has not meaningfully changed in decades.

Until now.

AppliedVR has built the world's first FDA-authorized prescription virtual reality therapy for chronic pain. Not a painkiller. Not a surgical procedure. A clinically validated, immersive therapeutic experience, delivered through a headset, prescribed by a physician, that has demonstrated significant reduction in pain intensity and pain interference in patients with chronic low back pain. Their flagship product, RelieVRx, represents a fundamentally new category of medicine: Immersive Therapeutics.

For the investors and operators in this room who just heard Curt Menefee talk about the future of human performance, this is that future. Athletes recovering from injury without opioids. Veterans managing chronic pain without dependency. Patients getting their lives back without a prescription that trades one crisis for another.

Matthew Stoudt co-founded AppliedVR in 2015 with the conviction that the most powerful computing platform for human healing was immersive reality. He has since raised over $70 million, built a clinical evidence base that cleared the FDA, and created a company that is not competing in healthcare, it is redefining it.